The Effects of Acupuncture and the Therapist´s Communication on Chemotherapy Induced Nausea and Vomiting
Primary Purpose
Breast Cancer, Colorectal Cancer, Bladder Cancer
Status
Recruiting
Phase
Not Applicable
Locations
Sweden
Study Type
Interventional
Intervention
Standard care
Sham acupuncture
Genuine acupuncture
Sponsored by
About this trial
This is an interventional supportive care trial for Breast Cancer
Eligibility Criteria
Inclusion Criteria:
- Patients of at least 18 years of age
- Breast, colorectal, bladder, testicular or prostate cancer
- Receiving adjuvant or neo-adjuvant intravenous chemotherapy inducing medium or high risk for emesis
- Willing and capable to give their informed consent and to take part of the treatment and data collection procedure
Exclusion Criteria:
- Consumption of antiemetics or experiences of persistent nausea, which will persist within 24 hours prior to the start of the chemotherapy session
- Hemophilia
- Former participation in the same study
Sites / Locations
- Sundsvall HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Other
Placebo Comparator
Experimental
Arm Label
Standard care (A)
Sham acupuncture (B)
Genuine acupuncture (C)
Arm Description
Standard care (A) with neutral communication (A1) or positive communication (A2)
Standard nausea treatment plus Sham acupuncture (B) with neutral communication (B1) or positive communication (B2)
Standard nausea treatment plus Genuine acupuncture (C) with neutral communication (C1) or positive communication (C2)
Outcomes
Primary Outcome Measures
Average nausea intensity day 1-5 (the day of the current chemotherapy session and the four following days).
Visual Analogue Scale (VAS).
Secondary Outcome Measures
The patient´s treatment expectations
Visual analogue scale (VAS)
Level of well-being
VAS
Level of well-being
Verbal category scales
Level of well-being
EQ-5D
Level of well-being
FACT-G
Level of activity
VAS
Level of activity
Verbal category scales
Level of activity
EQ-5D
Level of activity
FACT-G
Quality of life
VAS
Quality of life
Verbal category scales
Quality of life
EQ-5D
Quality of life
FACT-G
Full Information
NCT ID
NCT03232541
First Posted
July 24, 2017
Last Updated
October 12, 2022
Sponsor
Västernorrland County Council, Sweden
Collaborators
Linkoeping University, Västervik Hospital, Falu Hospital
1. Study Identification
Unique Protocol Identification Number
NCT03232541
Brief Title
The Effects of Acupuncture and the Therapist´s Communication on Chemotherapy Induced Nausea and Vomiting
Official Title
The Effects of Acupuncture and the Therapist´s Communication on Chemotherapy Induced Nausea and Vomiting: a Randomized, Sham-controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
October 2022
Overall Recruitment Status
Recruiting
Study Start Date
September 1, 2017 (Actual)
Primary Completion Date
June 2023 (Anticipated)
Study Completion Date
June 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Västernorrland County Council, Sweden
Collaborators
Linkoeping University, Västervik Hospital, Falu Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Background: Nausea and vomiting (emesis) is a common and burdensome side-effect of emetogenic chemotherapy. Emesis affects both the patient's quality of life and induces high costs within the health-care system. Many patients are interested in acupuncture, despite weak scrientific evidence for its effects beside non-specific effects. Few credibly sham-controlled studies have previously been conducted. The therapist's care and communication during acupuncture as well as during standard care may induce non-specific effects, such as placebo effects, potentially driven by the patient's expectations. It is not known if the type of communication, in terms of how positive the therapist communicates regarding expected effects, affects the effect of antiemetic treatments.
Aims: To investigate if chemotherapy-induced emesis, treatment expectancy and quality of life differ between patients who receive A) standard care including antiemetics, B) standard care plus sham acupuncture or C) standard treatment plus genuine acupuncture by a therapist who emphasizes the positive expected outcomes of the treatment, compared to a therapist who communicates neutral regarding the expected outcomes.
Procedure: The eligible patients will be randomized to A) standard care, including antiemetics or to B) standard treatment plus sham acupuncture or C) standard treatment plus genuine acupuncture. Within the three groups, the patients are randomized to receive either neutral or positive communication with the therapist during the treatment.
Outcome measures: The primary outcome is intensity of nausea within the five days after the chemotherapy session in patients receiving positive or neutral communication. Data collection of nausea and vomiting, expectations, and quality of life is performed at baseline the day before the studied chemotherapy session, during 10 days after the studied chemotherapy session, and at a follow-up ten days after the last chemotherapy session.
Detailed Description
Background: Nausea and vomiting (emesis) is a common and burdensome side-effect of emetogenic chemotherapy. Emesis affects both the patient's quality of life and induces high costs within the health-care system. Many patients are interested in acupuncture, despite weak scrientific evidence for its effects beside non-specific effects. Few credibly sham-controlled studies have previously been conducted. The therapist's care and communication during acupuncture as well as during standard care may induce non-specific effects, such as placebo effects, potentially driven by the patient's expectations. It is not known if the type of communication, in terms of how positive the therapist communicates regarding expected effects, affects the effect of antiemetic treatments.
Aims: To investigate if chemotherapy-induced emesis, treatment expectancy and quality of life differ between patients who receive A) standard care including antiemetics, B) standard care plus sham acupuncture or C) standard treatment plus genuine acupuncture by a therapist who emphasizes the positive expected outcomes of the treatment, compared to a therapist who communicates neutral regarding the expected outcomes.
Procedure: Patients undergoing chemotherapy for cancer at three Swedish oncology departments will receive written and oral study information and are screened for study criteria. The eligible patients will be randomized to A) standard care, including antiemetics or to B) standard treatment plus sham acupuncture or C) standard treatment plus genuine acupuncture. Within the three groups, the patients are randomized to receive either neutral or positive communication with the therapist during the treatment.
Outcome measures: The primary outcome is intensity of nausea within the five days after the chemotherapy session in patients receiving positive or neutral communication. Data collection of nausea and vomiting, expectations, and quality of life is performed at baseline the day before the studied chemotherapy session, during 10 days after the studied chemotherapy session, and at a follow-up ten days after the last chemotherapy session.
Qualitative interviews regarding the patients' experiences of the communication with the professionals are conducted with a strategicaly selected group of patients from all randomization combinations. The selection aims to provide heterogenicity.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer, Colorectal Cancer, Bladder Cancer, Testicular Cancer, Prostate Cancer, Chemotherapy-induced Nausea and Vomiting
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Factorial Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Masking Description
All other care providers beside the acupuncture/sham providing therapists are blinded to randomization group. For example, care providers providing the standard care antiemetic treatment and the chemotherapy per se are blinded for randomization group.
Allocation
Randomized
Enrollment
288 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Standard care (A)
Arm Type
Other
Arm Description
Standard care (A) with neutral communication (A1) or positive communication (A2)
Arm Title
Sham acupuncture (B)
Arm Type
Placebo Comparator
Arm Description
Standard nausea treatment plus Sham acupuncture (B) with neutral communication (B1) or positive communication (B2)
Arm Title
Genuine acupuncture (C)
Arm Type
Experimental
Arm Description
Standard nausea treatment plus Genuine acupuncture (C) with neutral communication (C1) or positive communication (C2)
Intervention Type
Other
Intervention Name(s)
Standard care
Intervention Description
A) Ordinary nausea treatment means receiving ordinary antiemetic medications. Within the group, the patients will be randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected antiemetic effects of their treatment, using a standardized communication model.
Intervention Type
Device
Intervention Name(s)
Sham acupuncture
Intervention Description
B) Sham acupuncture is administered bilaterally to a non-acupuncture point two body-inches proximal and one body-inch radial from PC6 using the telescopic Park Sham Device. The sham-needle is blunt and glides upward into its handle instead of penetrating. Marking tubes hold the needle in place. The therapist gives an illusion of manipulating the needle by turning it three times until it touches the skin, but no specific needle sensation ("deqi") will occur. Within the group, the patients will be randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected antiemetic effects of their treatment, using a standardized communication model.
Intervention Type
Device
Intervention Name(s)
Genuine acupuncture
Intervention Description
C) Acupuncture will be administered bilaterally to the standard antiemetic point PC6 located two body-inches proximal of the wrist crease, between the tendons of palmaris longus and flexor carpi radialis. Sharp acupuncture needles will be inserted into a depth of a half body-inch. The needles will be manipulated three times (at the start, middle and end of the treatment session) by twirling and lifting until deqi occurres. Within the group, the patients will be randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected antiemetic effects of their treatment, using a standardized communication model.
Primary Outcome Measure Information:
Title
Average nausea intensity day 1-5 (the day of the current chemotherapy session and the four following days).
Description
Visual Analogue Scale (VAS).
Time Frame
In the morning of day 1-5 (the day of chemotherapy and the four following days).
Secondary Outcome Measure Information:
Title
The patient´s treatment expectations
Description
Visual analogue scale (VAS)
Time Frame
Every morning day 1-10 (the day of the current chemotherapy session and the 10 following days).
Title
Level of well-being
Description
VAS
Time Frame
Three times: The day before the current chemotherapy session, 10 days after the current chemotherapy session, and 10 days after the very last chemotherapy session.
Title
Level of well-being
Description
Verbal category scales
Time Frame
Three times: The day before the current chemotherapy session, 10 days after the current chemotherapy session, and 10 days after the very last chemotherapy session.
Title
Level of well-being
Description
EQ-5D
Time Frame
Three times: The day before the current chemotherapy session, 10 days after the current chemotherapy session, and 10 days after the very last chemotherapy session.
Title
Level of well-being
Description
FACT-G
Time Frame
Three times: The day before the current chemotherapy session, 10 days after the current chemotherapy session, and 10 days after the very last chemotherapy session.
Title
Level of activity
Description
VAS
Time Frame
Three times: The day before the current chemotherapy session, 10 days after the current chemotherapy session, and 10 days after the very last chemotherapy session.
Title
Level of activity
Description
Verbal category scales
Time Frame
Three times: The day before the current chemotherapy session, 10 days after the current chemotherapy session, and 10 days after the very last chemotherapy session.
Title
Level of activity
Description
EQ-5D
Time Frame
Three times: The day before the current chemotherapy session, 10 days after the current chemotherapy session, and 10 days after the very last chemotherapy session.
Title
Level of activity
Description
FACT-G
Time Frame
Three times: The day before the current chemotherapy session, 10 days after the current chemotherapy session, and 10 days after the very last chemotherapy session.
Title
Quality of life
Description
VAS
Time Frame
Three times: The day before the current chemotherapy session, 10 days after the current chemotherapy session, and 10 days after the very last chemotherapy session.
Title
Quality of life
Description
Verbal category scales
Time Frame
Three times: The day before the current chemotherapy session, 10 days after the current chemotherapy session, and 10 days after the very last chemotherapy session.
Title
Quality of life
Description
EQ-5D
Time Frame
Three times: The day before the current chemotherapy session, 10 days after the current chemotherapy session, and 10 days after the very last chemotherapy session.
Title
Quality of life
Description
FACT-G
Time Frame
Three times: The day before the current chemotherapy session, 10 days after the current chemotherapy session, and 10 days after the very last chemotherapy session.
Other Pre-specified Outcome Measures:
Title
Cost-analyzes.
Description
Costs per patient, in relation to emesis outcomes and in relation to quality of life.
Time Frame
Emesis outcomes are measured every morning day 1-10 (the day of the current chemotherapy session and the 10 following days).
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients of at least 18 years of age
Breast, colorectal, bladder, testicular or prostate cancer
Receiving adjuvant or neo-adjuvant intravenous chemotherapy inducing medium or high risk for emesis
Willing and capable to give their informed consent and to take part of the treatment and data collection procedure
Exclusion Criteria:
Consumption of antiemetics or experiences of persistent nausea, which will persist within 24 hours prior to the start of the chemotherapy session
Hemophilia
Former participation in the same study
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ylva Widgren, MSP
Phone
+46 70 089 68 71
Email
ylva.widgren@liu.se
First Name & Middle Initial & Last Name or Official Title & Degree
Anna E Enblom, PhD
Phone
+46 70 089 51 49
Email
anna.enblom@liu.se
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anna E Enblom, PhD
Organizational Affiliation
Linkoeping University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Sundsvall Hospital
City
Sundsvall
ZIP/Postal Code
SE-85186
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ylva Widgren
Email
ylva.widgren@liu.se
12. IPD Sharing Statement
Learn more about this trial
The Effects of Acupuncture and the Therapist´s Communication on Chemotherapy Induced Nausea and Vomiting
We'll reach out to this number within 24 hrs